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Background: Cyclophosphamide (Cy) is used in combination
with novel drugs for the treatment of newly diagnosed and
relapsedmultiplemyeloma (MM). In this retrospective study,
we report the University of Florida experience with Cy
maintenance therapy in patients who could not tolerate or
previously failed 1st line maintenance therapy after autolo-
gous stem cell transplantation (ASCT).
Methods: We evaluated MM patients who received in-
duction chemotherapy and ASCT from 2000 to 2010. The
patients were divided into four groups based on the main-
tenance therapy prescribed post ASCT or after ﬁrst relapse:
No maintenance (observation), interferon and/or prednisone
(I/P), immunomodulatory drugs (IMiDs; thalidomide or
lenalidomide), and Cy. Overall 32 patients received Cy for
maintenance. Cy was given as 200 mg/day orally x 10 days
every 28 days (n¼28) or IV 750 mg/m2 every 21 days (n¼4).
Progression free survival (PFS) and overall survival (OS) was
analyzed using the log-rank test. Group characteristics were
studied using descriptive statistics.
Results: 286 patients underwent ASCT; patients with less
than six months of post-ASCT follow-up (8) and those
treated with allogeneic transplant (21) were excluded. Of the
remaining 257 patients, 36 patients received tandem ASCT.
The cohort was 45.9% female with a mean age at diagnosis of
57.4 years. Eleven patients had Cy maintenance post ASCT
(Cy1) and 21 received Cy after 1st relapse and salvage
chemotherapy (Cy2). Median PFS (from ASCT) and OS (from
diagnosis) for the entire Cy group was 22.6 and 76 months,respectively. After ASCT, patients in the Cy1 group had
similar disease stage distribution but a lower rate of VGPR/CR
(18.2%) in comparison to the other groups. There was no
signiﬁcant difference in PFS or OS in the Cy1 group vs. the
IMiDs (n¼75) or the observation (n¼ 105) groups. Patients
treated with IMiDs maintenance had signiﬁcantly longer PFS
(P¼0.001) and OS (P¼0.0322) vs. observation. Cy was well
tolerated with a dose reduction necessary in one patient due
to cytopenias. A similar analysis for Cy2 showed no signiﬁ-
cant difference in PFS and OS between Cy and other main-
tenance therapies. Speciﬁcally, there was no signiﬁcant
difference in PFS (10.4 vs.17.6months, p¼0.07) and OS (mean
91.7 vs. 95.7 months, p¼0.08) of patients receiving Cy2 when
compared to the IMiDs group (n¼31). IMiDs maintenance
therapy again demonstrated superior OS in comparison to
observation (p ¼ 0.018) in the second-line setting. Cy2 was
well tolerated with dose reductions necessary in 3/21 pa-
tients (cytopenias [2] and nausea [1]); Cy was discontinued
in 4/21 due to cytopenias. One patient in Cy1 group devel-
oped hypoplastic myelodysplastic syndrome after > 3 years
on Cy.
Conclusions: Cy maintenance therapy may be an effective
and well-tolerated alternative after ASCT, particularly in the
second-line setting, and when other maintenance options
are not feasible.
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Background: Lymphoma represents the third most common
cancer under 15yrs of age and the most common cancer in
adolescents and young adults.(Hochberg/Cairo, BJH 2009)
Hodgkin Lymphoma occurs in approximately 7,500 people
per yr in the U.S. EBV infection has been suggested to be one
of several causative possibilities in its pathogenesis with
about 40% of HL being EBV-associated. Autologous T cells
directed to LMP1/2 antigens can induce durable responses in
high risk patients without signiﬁcant toxicity.(Bollard, JCO
2014) Although there have been signiﬁcantly improved
outcomes, those with progressive or relapsed disease often
require alternative strategies with limited good options.
Objectives: We intend to analyze the toxicity and overall
response rate of allogeneic HLA matched donor derived
latent membrane protein (LMP) speciﬁc-cytotoxic T cell
lymphocytes (CTLs) in children, adolescents and young
adults (CAYA) with EBV-associated refractory or relapsed
Hodgkin lymphoma (HL) following reduced intensity
